T2 Biosystems, Lexington, Mass, has been awarded an innovative technology contract from Vizient, Irving, Texas, covering its T2Dx instrument, as well as the T2Bacteria and T2Candida panels, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.

Vizient awards innovative technology contracts for technologies that demonstrate an ability to enhance clinical care and reduce the risk of harm to patients or providers, while simultaneously raising the standard of patient care and safety.


John Sperzel, T2 Biosystems.

“This multiyear agreement with the nation’s largest group purchasing organization demonstrates the value that T2 Biosystems’ unique technology confers to patients who are suspected of having sepsis,” says John Sperzel, president and chief executive officer of T2 Biosystems. “T2 Biosystems is the only company with solutions that can detect sepsis-causing pathogens directly from whole blood in hours instead of days. With the mortality of patients in septic shock rising by 8% every hour they are not on targeted treatment, the need for hospitals to have more effective rapid diagnostics that enable earlier targeted therapy integrated into their infection management protocol is essential.”

The new contract provides Vizient members access to broader exposure and contracted pricing for the T2Dx instrument and its corresponding panels that detect sepsis-causing bacterial and fungal pathogens.

For more information, visit T2 Biosystems.